Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-10-30
2011-11-08
Seaman, D M (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S300000
Reexamination Certificate
active
08053433
ABSTRACT:
The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.
REFERENCES:
patent: 6335342 (2002-01-01), Longo et al.
patent: 6486322 (2002-11-01), Longo et al.
patent: 6579882 (2003-06-01), Stewart et al.
patent: 2003/0165576 (2003-09-01), Fujii et al.
patent: 2004/0198737 (2004-10-01), Cox et al.
patent: 2006/0106020 (2006-05-01), Rodgers et al.
patent: 3036390 (1982-05-01), None
patent: 0641781 (1995-03-01), None
patent: 0956865 (2009-11-01), None
patent: WO 99/62908 (1999-12-01), None
patent: WO 99/65908 (1999-12-01), None
patent: WO 99/65909 (1999-12-01), None
patent: WO 01/42246 (2001-06-01), None
patent: WO 02/00661 (2002-01-01), None
patent: WO 02/060492 (2002-08-01), None
patent: WO 02/096909 (2002-12-01), None
patent: WO03/000688 (2003-01-01), None
patent: WO 03/048162 (2003-06-01), None
patent: WO 2004/047843 (2004-06-01), None
patent: WO 2004/099204 (2004-11-01), None
patent: WO 2004/099205 (2004-11-01), None
patent: WO 2005/051393 (2005-06-01), None
patent: WO 2005/060972 (2005-07-01), None
patent: WO 2005/105146 (2005-11-01), None
patent: WO 2005/105814 (2005-11-01), None
patent: WO 2006/013114 (2006-02-01), None
patent: WO 2006/056399 (2006-06-01), None
Mullighan et al., Clinical cancer Research, (2011), 17(3), pp. 396-400.
McGlynn et al., British journal of Cancer (2007), 97, pp. 378-383.
Fang et al., Experimental cell research (2006), 312, 1229-1239.
Burdelya et al., Molecular cancer therapeutics (2002), vol. 1, pp. 893-899.
Kupferman et al., Journal of experimental therapeutics and Oncology, (2009), vol. 82 pp. 117-127.
Annelie et al., AIDs research and human retroviruses, (2007), 23(3), pp. 398-406.
Kryworuchko et al., Clin Exp Immunol 92003), 131, pp. 422-427.
Wang et al., Lupus (2010), 19, pp. 1171-1180.
Wertz et al., Nutrition and cancer (2009), 61(6), pp. 775-783.
Chang et al., the journal Immunology, (2009), 183, pp. 2183-2192.
Extended European Search Report dated Jul. 27, 2010 for EP Application No. 05854854.6 (15 pages).
Adv Pharmacol. 2000;47:113-74.
Agents Actions. Jan. 1993;38(1-2):116-21.
Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
Candotti, F., L. Notarangelo, et al. (2002). “Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways.” J Clin Invest 109(10): 1261-9).
Candotti, F., S. A. Oakes, et al. (1997) “Structural and functional basis for JAK3-deficient severe combined immunodeficiency.” Blood 90(10): 3996-4003).
Cetkovic-Cvrlje, M., A. L. Dragt, et al. (2003). “Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice.” Clin Immunol 106(3): 213-25.
De Vos, J., M. Jourdan, et al. (2000). “JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells.” Br J Haematol 109(4): 823-8.
Gottlieb, A.B., et al, Nat Rev Drug Disc., 4:19-34.
Immunol Today. Jan. 1998;19(1):37-44.
Ishizaki et al., Molecular Pharmacology, “Pharmacological properties of &-27632, a specific inhibitor of Pho-Associated kinases”, vol. 57:976-83 (2000).
JCI, 113:1664-1675.
Journal of Pharmaceutical Science, 66, 2 (1977).
Kawamura, M., D. W. McVicar, et al. (1994). “Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes.” Proc Natl Acad Sci U S A 91(14): 6374-8.
Levine, et al., Cancer Cell, vol. 7, 2005: 387-397.
Neubauer, H., A. Cumano, et al. (1998). Cell 93(3): 397-409.
Nishio et al., FEBS Letters, “Tyrosine kinase-dependent modulation by interfereon-a of the ATP-sensitive K+ current in rabbit ventricular myocytes”, vol. 445, pp. 87-91 (1999).
Ortmann, R. A., T. Cheng, et al. (2000). “Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation.” Arthritis Res 2(1): 16-32).
Parganas, E., D. Wang, et al. (1998). Cell 93(3): 385-95.
Park et al., Analytical Biochemistry 1999, 269, 94-104.
Perris, A. B. and P. B. Rothman (2002). “JAK-STAT signaling in asthma.” J Clin Invest 109(10): 1279-83.
Pirard et al., Journal of chemical information and computer sciences, “Classification of kinase inhibitors using BCUT descriptors”, vol. 40:1431-40 (2000).
Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA., 1985, p. 1418.
Rodig, S. J., M. A. Meraz, et al. (1998). “Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses.” Cell 93(3): 373-83).
Saemann, M. D., C. Diakos, et al. (2003). “Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3.” Am J Transplant 3(11): 134-19.
Scott, M. J., C. J. Godshall, et al. (2002). “Jaks, STATs, Cytokines, and Sepsis.” Clin Diagn Lab Immunol 9(6): 1153-9.
Seto, Y., H. Nakajima, et al. (2003). “Enhanced Th2 cell-mediated allergic inflammation in Tyk2-deficient mice.” J Immunol 170(2): 1077-83.
T. Higuchi and V. Stella, “Pro-drugs as Novel Delivery Systems,” vol. 14 of the A.C.S. Symposium Series.
T.W. Green and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd. Ed., Wiley & Sons, Inc., New York (1999).
Takemoto, S., J. C. Mulloy, et al. (1997). “Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins.” Proc Natl Acad Sci U S A 94(25): 13897-902.
Wu et al., Organic Letters, “One-Pot Two-step microwave-assisted reaction in constructing 4,5-disubstituted pyrazolopyrimidines”, vol. 5:3587-90 (2003).
International Search Report for PCT/US2005/046207.
Combs Andrew P.
Rodgers James D.
Sparks Richard B.
Wang Haisheng
Fish & Richardson P.C.
Ineyte Corporation
Rahmani Niloofar
Seaman D M
LandOfFree
Pyrrolo[2,3-b]pyridin-4-yl-amines and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolo[2,3-b]pyridin-4-yl-amines and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolo[2,3-b]pyridin-4-yl-amines and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4259454